Primary Source Link. Access the full editorial on the CDSCO’s new compounding guidelines here: https://epaper.thehindu.com/ccidist-ws/th/th_international/issues/165318/OPS/G8GFCIPO6.1+G0FFDQ1QJ.1.html
Operationalizing Legal Shifts. The Central Drugs Standard Control Organization (CDSCO) has released guidelines that operationalize changes to the Drugs and Cosmetics Act, 1940, which have been in development since 2023.
The Jan Vishwas Foundation. The legal basis is the Jan Vishwas Act, designed to “decriminalize and rationalize” minor offenses to improve the ease of doing business in India’s pharmaceutical sector.

Source

Settlement over Litigation. Compounding allows firms to settle certain offenses by reporting them and paying a prescribed fine instead of facing criminal prosecution and lengthy court trials.
Discretionary Immunity. Firms granted compounding receive “immunity from prosecution” for that specific case, provided they meet the conditions set by the regulator.
Flexible Timing. Applications for compounding can be made “before or after” the initiation of prosecution, offering a window for firms to rectify technical lapses early.

Inclusion of Section 32B. The Jan Vishwas Act broadened Section 32B to include offenses such as manufacturing or distributing drugs in breach of the Act, provided they are not spurious or adulterated.
Exclusion of Severe Crimes. Serious violations covered under Section 27(a-c)—such as the production of adulterated or life-threatening drugs—remain non-compoundable and subject to full criminal penalties.
Focus on Technicalities. The guidelines are primarily intended for record-keeping errors, disclosure lapses, and other administrative non-compliance that do not directly endanger public health.

Reducing Judicial Burden. By settling minor issues out of court, the regulatory apparatus prevents the needless criminalization of technical errors and reduces the backlog in the legal system.
Resource Optimization. Enforcement agencies can shift their focus away from paperwork lapses and toward “direr violations” that pose genuine risks to consumers.
Business Predictability. The move fosters an environment of “ease of living” for legitimate businesses that may have committed inadvertent or minor procedural mistakes.

Erosion of Deterrence. There is a significant risk that the guidelines could regress into a “pay and pass” scheme where firms view fines merely as a cost of doing business rather than a reason to improve.
Inconsistent Application. If compounding fines are set too low or applied inconsistently, they may fail to incentivize the rigorous quality standards required in medicine manufacturing.
Compliance Faltering. Without the threat of criminal prosecution for substantive failures, general industry compliance might weaken over time.

Lack of Public Disclosure. The CDSCO currently does not mandate the publication of compounding orders or the specific details of the underlying cases.
Public Faith at Risk. Without transparent reporting, the public may lose trust in the regulator’s ability to hold the pharmaceutical industry accountable behind closed doors.
Need for Auditable Trails. Independent actors require a publicly auditable trail to verify that the regulator’s discretion is being used fairly and effectively.

Repeat Offender Restrictions. The guidelines specify that repeat offenders cannot avail of the compounding benefit, but enforcing this requires robust data tracking.
The Role of Public Reporting. Publicly available records are essential to allow whistle-blowers and consumer groups to identify and flag firms that consistently fail to meet standards.
Inclusion of Stakeholders. Current processes do not provide a platform for consumer representations to be heard before immunity is granted to a company.

Broad Language Pitfalls. The description of compoundable errors is broad enough to potentially cover a wide range of behaviors, from simple typos to significant compliance failures.
Risk of Substantive Lapses. Regulators must be careful not to allow substantive failures to be “masked” as mere technicalities during the discretionary review process.
Standardizing SOPs. Clear Standard Operating Procedures (SOPs) are necessary to ensure that discretion does not lead to favoritism or arbitrary decision-making.

Corrective and Preventive Actions (CAPA). Compounding must be strictly linked to CAPA, ensuring that the firm identifies and fixes the root cause of the violation.
Follow-up Inspections. The regulator should conduct mandatory follow-up inspections after a compounding order is settled to ensure the technical lapse has been permanently resolved.
Public Alerts. In relevant cases, the CDSCO should still issue public alerts or direct product recalls, even if the legal prosecution has been settled through a fine.

Maintaining Public Health Priority. The primary goal of the CDSCO must remain drug safety, even as it attempts to streamline business operations for the industry.
Balancing Ease and Safety. While “ease of business” is a valid economic goal, it should not come at the cost of weakening India’s reputation as a reliable global pharmacy.
The Need for Evolution. The guidelines should be viewed as a living document that must be adjusted if evidence suggests that drug quality is declining under the new regime.

CDSCO Compounding Guidelines Quiz

Instructions

Total Questions: 15

Time: 15 Minutes

Each question has 5 options. Multiple answers may be correct.

Time Left: 15:00